Nippon Life Global Investors Americas Inc. Sells 4,460 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Nippon Life Global Investors Americas Inc. lessened its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,330 shares of the medical research company's stock after selling 4,460 shares during the period. Nippon Life Global Investors Americas Inc.'s holdings in IQVIA were worth $8,515,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in IQVIA in the 4th quarter worth about $33,000. GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA in the 4th quarter valued at $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA in the 4th quarter valued at $44,000. Zions Bancorporation N.A. increased its stake in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Performance

NYSE IQV traded down $0.30 during trading on Friday, hitting $150.38. 1,333,062 shares of the company's stock traded hands, compared to its average volume of 1,423,433. The stock has a market capitalization of $26.51 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The business has a 50 day moving average of $171.60 and a 200-day moving average of $193.55.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on IQV shares. Morgan Stanley lifted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Barclays reiterated an "equal weight" rating and issued a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Finally, BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $237.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.